In this study, we utilized an antibody–drug conjugate (ADC) comprising an anti-uPARAP mAb conjugated to monomethyl auristatin E via a protease-sensitive linker for preclinical studies on mesothelioma treatment. Here, MRC2 is linked to mesothelioma.